Heska (HSKA) Set to Announce Earnings on Thursday


Share on StockTwits

Heska (NASDAQ:HSKA) will be posting its quarterly earnings results before the market opens on Thursday, May 6th. Analysts expect Heska to post earnings of ($0.16) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Heska (NASDAQ:HSKA) last announced its earnings results on Monday, February 22nd. The medical research company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.47. The business had revenue of $64.30 million during the quarter, compared to analyst estimates of $53.10 million. Heska had a negative net margin of 11.15% and a negative return on equity of 2.29%. The firm’s quarterly revenue was up 90.2% on a year-over-year basis. On average, analysts expect Heska to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of HSKA opened at $191.14 on Wednesday. The firm has a market cap of $1.99 billion, a PE ratio of -86.10 and a beta of 1.65. The company has a current ratio of 4.96, a quick ratio of 3.79 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $176.86 and a two-hundred day simple moving average of $158.49. Heska has a 1-year low of $68.04 and a 1-year high of $217.17.

HSKA has been the subject of several analyst reports. Zacks Investment Research lowered Heska from a “buy” rating to a “sell” rating in a research note on Tuesday, April 27th. Alliance Global Partners restated a “buy” rating and issued a $230.00 price objective (up from $167.50) on shares of Heska in a research note on Wednesday, February 24th. Raymond James upped their price objective on Heska from $145.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 3rd. Piper Sandler upped their price objective on Heska from $157.00 to $220.00 and gave the stock an “overweight” rating in a research note on Monday, March 1st. Finally, JPMorgan Chase & Co. began coverage on Heska in a research note on Friday, January 29th. They issued an “overweight” rating and a $195.00 price target for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $216.20.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus +TM veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Featured Article: Investing strategies using the yield curve

Earnings History for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.